Increased Aygestin (Norethindrone) dose?

Although this risk was lower than among users of estrogen or progestin of high power, the irregularity was not statistically significant.Work-clothes use of oral contraceptive pills was associated with a 50% occurrence in epithelial ovarian residence risk.
In all categories of oral contraceptive pills by aptitude, ORs ranged from 0.62 for high estrogen and high progestin to 0.19 for low estrogen and low progestin users vs never users of hormonal contraception.
Attributable risk for not using any combined oral contraceptive pills was about 42% and for not using low estrogen and low progestin formulations was about 73% (ie, up to 42% of ovarian cancers might have been avoided if all women used some form of combined oral contraceptive pill, and about 73% of ovarian cancers might have been avoided if all women used low estrogen and low progestin oral contraceptive pills.
All users of oral contraceptive pills had significantly lower odds of developing invasive ovarian carcinoma when compared with never users.In a subset of 205 women with exclusive use of Aygestin (Norethindrone) (76 cases; 129 controls), users of 0.5 mg or less had a significantly reduced risk for ovarian Crab vs women using 10 mg.
Increased Aygestin (Norethindrone) dose was linked with a significant gain in ovarian carcinoma risk, indicating a dose-response someone ( P for nature = .02).
Pearls for Praxis Compared with women who never used hormonal contraception, users of oral contraceptive pills with low estrogen (? 0.035 mg of ethinyl E2) and low progestin (Norethindrone), users of 0.5 mg or less had a significantly reduced risk for ovarian build vs women using 10 mg.
This is a part of article Increased Aygestin (Norethindrone) dose? Taken from "Aygestin Norethindrone Acetate" Information Blog